Andrea (Flynn) Franson, MD, MS
Clinical Assistant Professor of Pediatrics
Fellowship Director of Pediatric Hematology/Oncology
D4202 MPB
Ann Arbor
MI, 48109-5718

Available to mentor
Andrea (Flynn) Franson, MD, MS
Clinical Assistant Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    Dr. Andrea (Flynn) Franson is a Pediatric Oncologist in the Department of Pediatrics at the University of Michigan. She received her bachelor’s degree from Rensselaer Polytechnic Institute in Troy, New York and her medical degree from the University of Michigan Medical School. She completed her residency in Pediatrics and fellowship in Pediatric Hematology/Oncology at the Children’s Hospital of Philadelphia (CHOP). During fellowship, she earned a master’s degree in Pharmacology from Thomas Jefferson University. She joined as faculty at the University of Michigan in 2019.

    Links
    Qualifications
    • Fellowship
      Children's Hospital of Philadelphia, Pediatric Hematology and Oncology, 2017
    • Clinical Pharmacology Fellow
      Thomas Jefferson University, Pharmacology and Experimental Therapeutics, 2017
    • Residency
      Children's Hospital of Philadelphia, Pediatrics, 2014
    • Internship
      Children's Hospital of Philadelphia, Pediatrics, 2012
    • MS, Pharmacology
      Thomas Jefferson University, 130 S. Ninth Street, Suite 100, 2017
    • MD
      University of Michigan, Ann Arbor, 2011
    • BS
      Rensselaer Polytechnic Institute, Troy, 2007
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    Broadly, Dr. Franson's research interests are in the clinical translation of promising therapeutic approaches from the lab into pediatric patients with high-risk brain tumors. She collaborates with several basic science laboratories on campus to move successful compounds or immunotherapies into pediatric and AYA focused clinical trials, with an interest in novel clinical trial designs and the use of PK/PD-informed dosing.

    Recent Publications See All Publications
    • Journal Article
      Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions
      Lamoureux A-A, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong T-T, Liu Y-L, Wu K-S, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer J-P, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O’Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S. Clinical Cancer Research, DOI:10.1158/1078-0432.ccr-24-0581
    • Proceeding / Abstract / Poster
      BIOM-43. SOMATICTP53, PIK3R1, NF1 ORTERT MUTATIONS ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOME IN H3K27M-ALTERED DIFFUSE MIDLINE GLIOMA: AN INTERNATIONAL, MULTI-INSTITUTIONAL STUDY
      Nguyen T, Lerman B, Stoller S, Müller T, Comfort L, Leal-Ekman S, Lyons S, Holman L, Lucas CH, Banerjee A, Reddy A, Gupta N, Whipple N, Gerber N, Stuecklin A, Areza E, Marion R, Knowles T, Solomon D, Franson A, Koschmann C, Partap S, Monje M, Prolo L, Cheshier S, Antony R, Bhatia A, Foster J, LaRiviere M, Maule L, Carrion AW, Kline C, Bruningk S, Nazarian J, Waszak S, Mueller S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii29 - viii29. DOI:10.1093/neuonc/noae165.0116
    • Proceeding / Abstract / Poster
      CTNI-09. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
      Perreault S, Khuong-Quang D-A, Kilburn LB, Landi DB, Leary SES, Bailey S, Larouche V, Nysom K, Driever PH, Baxter PA, Witt O, Oren MY, Abdelbaki MS, Kline C, Whipple NS, Ziegler DS, van der Lugt J, Hassall TE, Gerber NU, Segal D, Hansford JR, McCowage G, Kang HJ, Han JW, Hargrave D, Franson AT, Toledano H, Jabado N, Gottardo NG, N S, Oren L, Tan EEK, Mueller S, Hoke ME, Kim Y, Walter A, Da Costa D, Manley P, Waanders AJ. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii96 - viii97. DOI:10.1093/neuonc/noae165.0377
    • Proceeding / Abstract / Poster
      CTNI-78. PNOC008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA)
      Kilburn L, Franson A, Cooney T, Kline C, Stoller S, Reddy A, Banerjee A, Packer R, Bendel A, Skrypek M, Minturn J, Abdelbaki M, Whipple N, Chan P, Crawford J, Crotty E, Waanders A, Elster J, Raabe E, George E, Pinto S, Supakul N, Kraya A, Prados M, Nazarian J, Solomon D, Long-Boyle J, Molinaro A, Waszak S, Mueller S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii115 - viii115. DOI:10.1093/neuonc/noae165.0445
    • Proceeding / Abstract / Poster
      NCOG-05. HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
      Peipert J, Baxter PA, Yu S, Oestreicher N, Zelt S, Driever PH, Bailey S, McCowage G, Ziegler DS, Witt O, Kang HJ, Hassall TE, Han JW, Franson AT, Oren MY, Toledano H, Larouche V, Abdelbaki MS, Jabado N, Gottardo NG, Gerber NU, Whipple NS, Segal D, N S, Oren L, Tan EEK, Mueller S, Kilburn LB, Nysom K, Khuong-Quang D-A, Landi DB, van der Lugt J, Leary SES, Perreault S, Waanders AJ, Hargrave D, Kline C, McKenna C, Manley P, Raju SG, Hansford JR. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii224 - viii225. DOI:10.1093/neuonc/noae165.0887
    • Proceeding / Abstract / Poster
      NIMG-70. COMPARISON OF VOLUMETRIC AND CROSS-SECTIONAL MEASUREMENTS IN DIFFUSE MIDLINE GLIOMAS: RETHINKING RESPONSE ASSESSMENT
      Khalili N, Khalili N, Gandhi D, Franson A, Jain P, Anderson H, Tu W, Haldar S, Familiar A, Storm P, Ware J, Resnick A, Vossough A, Nabavizadeh A, Kazerooni AF. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii211 - viii211. DOI:10.1093/neuonc/noae165.0834
    • Journal Article
      Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion-Positive High-Grade Glioma.
      Simoneau J, Robertson P, Muraszko K, Maher CO, Garton H, Calvert R, Koschmann C, Upadhyaya SA, Mody R, Brown N, Kumar-Sinha C, Parmar H, Camelo-Piragua S, Franson AT. J Natl Compr Canc Netw, 2024 Sep; 22 (7): DOI:10.6004/jnccn.2024.7045
      PMID: 39236755
    • Proceeding / Abstract / Poster
      DIPG-77. SOMATICTP53,PIK3R1, NF1 ORTERT MUTATIONS ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOME IN H3K27M-ALTERED DIFFUSE MIDLINE GLIOMA
      Nguyen T, Lerman B, Stoller S, Müller T, Comfort L, Lyons S, Holman L, Lucas CH, Banerjee A, Reddy A, Gupta N, Whipple N, Gerber N, Stuecklin A, Areza E, Marion R, Knowles T, Solomon D, Franson A, Koschmann C, Partap S, Monje M, Prolo L, Cheshier S, Antony R, Bhatia A, Foster J, LaRiviere M, Maule L, Carrion AW, Kline C, Bruningk S, Nazarian J, Waszak SM, Mueller S. Neuro-Oncology, 2024 Jun 30; 26 (Supplement_4): DOI:10.1093/neuonc/noae064.130